Pfizer’s monthly berobenatide hit nausea-and-vomiting rates close to Wegovy’s mid-stage benchmark
The side-effect profile of a new monthly GLP-1 rival lands near Novo Nordisk’s weekly target, sharpening the obesity race.
By Khalid Al-Harbi·· 4 min
2 briefings · “pfizer”
The side-effect profile of a new monthly GLP-1 rival lands near Novo Nordisk’s weekly target, sharpening the obesity race.
The question is not if, but when. Policy analysts say Chinese drug outlicensing may turn into branded global sales by 10 to 15 years.